Street Cheers ImClone, but Analysts Remain Wary; The stock gained amid word of a fresh tussle between the drug outfit's board and Carl Icahn, who refused to support a $36 a share buyout bid

MLA

“Street Cheers ImClone, but Analysts Remain Wary; The Stock Gained amid Word of a Fresh Tussle between the Drug Outfit’s Board and Carl Icahn, Who Refused to Support a $36 a Share Buyout Bid.” Business Week Online, Oct. 2006. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.152385527&authtype=sso&custid=ns315887.

APA

Street Cheers ImClone, but Analysts Remain Wary; The stock gained amid word of a fresh tussle between the drug outfit’s board and Carl Icahn, who refused to support a $36 a share buyout bid. (2006, October 5). Business Week Online.

Chicago

Business Week Online. 2006. “Street Cheers ImClone, but Analysts Remain Wary; The Stock Gained amid Word of a Fresh Tussle between the Drug Outfit’s Board and Carl Icahn, Who Refused to Support a $36 a Share Buyout Bid,” October 5. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.152385527&authtype=sso&custid=ns315887.